Search Results
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
August, 2024
August 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jul
Vivek Subbiah
Nov 6, 2023, 03:26 |
Blog
Vivek Subbiah: How to build a successful phase 1 program?
Vivek Subbiah posted the following on X/Twitter: "How to build a successful phase 1 program? -…
Nov 2, 2023, 00:48 |
Blog
Vivek Subbiah: Wow! What an amazing event on “Shaping the future of personalised healthcare for cancer patients”
Vivek Subbiah, posted the following on LinkedIn: "Wow! What an amazing event on 'Shaping the…
Oct 18, 2023, 18:00 |
Drugs
Vivek Subbiah: My perspectives of tumor agnostic drug development
Vivek Subbiah recently shared on LinkedIn: "So honored to present the “Future of Tissue-Agnostic Precision…
Oct 18, 2023, 16:54 |
Drugs
Vivek Subbiah: Final efficacy and safety results of the ROAR phase 2 basket trial of dabrafenib in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on…
Oct 17, 2023, 01:32 |
Blog
Vivek Subbiah: Awesome poster presentation on Epha2 targeting by our amazing Dr. Elisa Fontana
Vivek Subbiah shared on LinkedIn: "Kudos to our amazing Sarah Cannon Research Institute Phase 1 clinical…
Oct 9, 2023, 18:18 |
Blog
Vivek Subbiah: Mark your calendars if you are attending the NCI AACR EORTC 2023- The triple meeting in Boston, Oct 11-15.
Vivek Subbiah shared on LinkedIn: “Mark your calendars if you are attending the NCI AACR…
Oct 5, 2023, 17:42 |
Insight
Vivek Subbiah: Still remember the 1st ever patient enrolled on the trial in the peak of the pandemic.
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at The Sarah Cannon Research Institute, on…
Oct 5, 2023, 17:41 |
Blog
Vivek Subbiah: Mark your calendars if you are attending the ESMO MAP23 meeting in Paris, France this week, Oct 4-6.
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on…
Oct 3, 2023, 18:02 |
Insight
Vivek Subbiah: Delighted to publish our editorial. TRKing sarcomas for precision medicine: Seek, and ye shall find! In the American Cancer Society Journal Cancer.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X/Twitter:…
Oct 2, 2023, 18:31 |
Opinion
Vivek Subbiah: What a fantastic meeting packed with everything that’s needed for an early-phase drug development program.
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on LinkedIn:…
18
19
20
21
22
All:
284
Posts:
191 - 200
Matti Aapro is running for the UICC Board of Directors
CityU-AFCR Symposium on Precision Medicine and Digital Medicine
New management team at St. Anna Children's Hospital
Key Inspirational Moments with WHO Director at the Olympic Games
Remembering Susan Wojcicki, Honoring a Legacy of Leadership and Technological Innovation
Facebook
RSS Feed
Twitter
Linkedin
Youtube